Zacks Investment Research downgraded Hercules Capital Inc (NYSE:HTGC) to Hold in a report released today.
- Updated: November 30, 2016
Zacks Investment Research has downgraded Hercules Capital Inc (NYSE:HTGC) to Hold in a report released on Wednesday November 30, 2016.
Previously on 11/29/2016, Zacks Investment Research reported on Hercules Capital Inc (NYSE:HTGC) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.09%.
Yesterday Hercules Capital Inc (NYSE:HTGC) traded -0.80% lower at $13.79. The company’s 50-day moving average is $13.53 and its 200-day moving average is $13.12. The last closing price is up 4.15% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 308,962 shares of the stock were exchanged, up from an average trading volume of 297,794
See Chart Below
Hercules Capital Inc has a 52 week low of $9.92 and a 52 week high of $14.00 with a P/E ratio of 14.69 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 10 brokers have issued a report on the stock. The consensus target price is $13.45 with 3 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 4 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Hercules Capital Inc (NYSE:HTGC)
Hercules Capital, Inc., formerly Hercules Technology Growth Capital, Inc., is a specialty finance company. The Company is focused on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services, including computer software and hardware; networking systems; semiconductors; semiconductor capital equipment; information technology infrastructure or services; Internet consumer and business services; telecommunications; telecommunications equipment, and media. Within the life science sub-sector, the Company focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, healthcare services and information systems companies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.